Recent Publications

Publications for Thomas J Conlon, PhD; Kirsten Coleman, and Kirsten Erger:

  1. Kondratov, O., Kondratova, L., Mandel, R. J., Coleman, K., Savage, M. A., Gray-Edwards, H. L., Ness, T. J., Rodriguez-Lebron, E., Bell, R. D., Rabinowitz, J., Gamlin, P. D., & Zolotukhin, S. (2021). A comprehensive study of a 29-capsid AAV library in a non-human primate central nervous system. Molecular therapy : the journal of the American Society of Gene Therapy, S1525-0016(21)00364-6. Advance online publication.
  2. Hamm, S. E., Fathalikhani, D. D., Bukovec, K. E., Addington, A. K., Zhang, H., Perry, J. B., McMillan, R. P., Lawlor, M. W., Prom, M. J., Vanden Avond, M. A., Kumar, S. N., Coleman, K. E., Dupont, J. B., Mack, D. L., Brown, D. A., Morris, C. A., Gonzalez, J. P., & Grange, R. W. (2021). Voluntary wheel running complements microdystrophin gene therapy to improve muscle function in mdx mice. Molecular therapy. Methods & clinical development21, 144–160.
  3. Daniel, H. D., Kumar, S., Kannangai, R., Lakshmi, K. M., Agbandje-Mckenna, M., Coleman, K., Srivastava, A., Srivastava, A., & Abraham, A. M. (2021). Prevalence of Adeno-Associated Virus 3 Capsid Binding and Neutralizing Antibodies in Healthy and Hemophilia B Individuals from India. Human gene therapy32(9-10), 451–457.
  4. Bolfer, L., Estrada, A. H., Larkin, C., Conlon, T. J., Lourenco, F., Taggart, K., Suzuki-Hatano, S., & Pacak, C. A. (2020). Functional Consequences of PDK4 Deficiency in Doberman Pinscher Fibroblasts. Scientific reports10(1), 3930.
  5. Byrne, B. J., Fuller, D. D., Smith, B. K., Clement, N., Coleman, K., Cleaver, B., Vaught, L., Falk, D. J., McCall, A., & Corti, M. (2019). Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy. Annals of translational medicine7(13), 290.
  6. Mondo, E., Moser, R., Gao, G., Mueller, C., Sena-Esteves, M., Sapp, E., Pfister, E., O’Connell, D., Takle, K., Erger, K. E., Liu, W., Conlon, T. J., DiFiglia, M., Gounis, M. J., & Aronin, N. (2018). Selective Neuronal Uptake and Distribution of AAVrh8, AAV9, and AAVrh10 in Sheep After Intra-Striatal Administration. Journal of Huntington’s disease7(4), 309–319.
  7. Song, C., Conlon, T. J., Deng, W. T., Coleman, K. E., Zhu, P., Plummer, C., Mandapati, S., Van Hoosear, M., Green, K. B., Sonnentag, P., Sharma, A. K., Timmers, A., Robinson, P. M., Knop, D. R., Hauswirth, W. W., Chulay, J. D., Shearman, M. S., & Ye, G. J. (2018). Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 Mice. Human gene therapy. Clinical development29(4), 188–197.
  8. Lee, Y. M., Conlon, T. J., Specht, A., Coleman, K. E., Brown, L. M., Estrella, A. M., Dambska, M., Dahlberg, K. R., & Weinstein, D. A. (2018). Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia. Journal of inherited metabolic disease41(6), 977–984.
  9. Conlon, T. J., & Mavilio, F. (2018). The Pharmacology of Gene and Cell Therapy. Molecular therapy. Methods & clinical development8, 181–182.
  10. Corti, M., Liberati, C., Smith, B. K., Lawson, L. A., Tuna, I. S., Conlon, T. J., Coleman, K. E., Islam, S., Herzog, R. W., Fuller, D. D., Collins, S. W., & Byrne, B. J. (2017). Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease. Human gene therapy. Clinical development28(4), 208–218.